311 related articles for article (PubMed ID: 28401443)
1. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.
Brilli L; Danielli R; Ciuoli C; Calabrò L; Di Giacomo AM; Cerase A; Paffetti P; Sestini F; Porcelli B; Maio M; Pacini F
Endocrine; 2017 Dec; 58(3):535-541. PubMed ID: 28401443
[TBL] [Abstract][Full Text] [Related]
2. Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.
Siddiqui MS; Lai ZM; Spain L; Greener V; Turajlic S; Larkin J; Morganstein DL
J Endocrinol Invest; 2021 Jan; 44(1):195-203. PubMed ID: 32449093
[TBL] [Abstract][Full Text] [Related]
3. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.
Iwama S; De Remigis A; Callahan MK; Slovin SF; Wolchok JD; Caturegli P
Sci Transl Med; 2014 Apr; 6(230):230ra45. PubMed ID: 24695685
[TBL] [Abstract][Full Text] [Related]
4. Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis.
De Sousa SMC; Sheriff N; Tran CH; Menzies AM; Tsang VHM; Long GV; Tonks KTT
Pituitary; 2018 Jun; 21(3):274-282. PubMed ID: 29380110
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.
Albarel F; Gaudy C; Castinetti F; Carré T; Morange I; Conte-Devolx B; Grob JJ; Brue T
Eur J Endocrinol; 2015 Feb; 172(2):195-204. PubMed ID: 25416723
[TBL] [Abstract][Full Text] [Related]
6. Pituitary enlargement following ipilimumab without long term endocrine dysfunction.
Nogueira E; Menon A; Dede A; Mitra I; Brock C; Larkin J; Morganstein D
Curr Probl Cancer; 2021 Dec; 45(6):100710. PubMed ID: 33622518
[TBL] [Abstract][Full Text] [Related]
7. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.
Ryder M; Callahan M; Postow MA; Wolchok J; Fagin JA
Endocr Relat Cancer; 2014 Apr; 21(2):371-81. PubMed ID: 24610577
[TBL] [Abstract][Full Text] [Related]
8. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab-induced hypophysitis, a single academic center experience.
Snyders T; Chakos D; Swami U; Latour E; Chen Y; Fleseriu M; Milhem M; Zakharia Y; Zahr R
Pituitary; 2019 Oct; 22(5):488-496. PubMed ID: 31327112
[TBL] [Abstract][Full Text] [Related]
10. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.
Min L; Hodi FS; Giobbie-Hurder A; Ott PA; Luke JJ; Donahue H; Davis M; Carroll RS; Kaiser UB
Clin Cancer Res; 2015 Feb; 21(4):749-55. PubMed ID: 25538262
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab Induced Hypophysitis: MRI Findings in a Series of 3 Cases.
Wadhwa V
J Ark Med Soc; 2017 May; 113(11):270-272. PubMed ID: 30351740
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.
Faje AT; Sullivan R; Lawrence D; Tritos NA; Fadden R; Klibanski A; Nachtigall L
J Clin Endocrinol Metab; 2014 Nov; 99(11):4078-85. PubMed ID: 25078147
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab-Induced Autoimmune Hypophysitis: Diagnostic and Management Challenges Illustrated by a Clinical Case.
Marques P; Grossman A
Acta Med Port; 2015; 28(6):775-9. PubMed ID: 27265913
[TBL] [Abstract][Full Text] [Related]
14. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with CTLA4-related hypophysitis.
Seejore K; Giannoudi M; Osborn D; Lynch JM; Al-Qaissi A; Dunwoodie E; Hook J; Marples M; Murray RD
Eur J Endocrinol; 2021 Dec; 186(1):83-93. PubMed ID: 34735371
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
Okano Y; Satoh T; Horiguchi K; Toyoda M; Osaki A; Matsumoto S; Tomaru T; Nakajima Y; Ishii S; Ozawa A; Shibusawa N; Shimada T; Higuchi T; Chikamatsu K; Yamada M
Endocr J; 2016 Oct; 63(10):905-912. PubMed ID: 27440480
[TBL] [Abstract][Full Text] [Related]
17. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.
Faje AT; Lawrence D; Flaherty K; Freedman C; Fadden R; Rubin K; Cohen J; Sullivan RJ
Cancer; 2018 Sep; 124(18):3706-3714. PubMed ID: 29975414
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports.
Marlier J; Cocquyt V; Brochez L; Van Belle S; Kruse V
Endocrine; 2014 Dec; 47(3):878-83. PubMed ID: 24554495
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series.
Lam T; Chan MM; Sweeting AN; De Sousa SM; Clements A; Carlino MS; Long GV; Tonks K; Chua E; Kefford RF; Chipps DR
Intern Med J; 2015 Oct; 45(10):1066-73. PubMed ID: 26010858
[TBL] [Abstract][Full Text] [Related]
20. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash.
Nallapaneni NN; Mourya R; Bhatt VR; Malhotra S; Ganti AK; Tendulkar KK
J Natl Compr Canc Netw; 2014 Aug; 12(8):1077-81. PubMed ID: 25099440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]